Concurrence of nivolumab ‐induced interstitial lung disease and cancer invasion
In conclusion, nivolumab‐related ILD and cancer invasion may concur and aggressive biopsy should be considered if nivolumab‐related ILD is refractory to immunosuppressive therapy.
Nivolumab‐related intersitital lung disease (ILD) may concur with cancer invasion in non‐small‐cell lung cancer (NSCLC) patients. These conditions are difficult to distinguish from each other by computed tomography (CT) findings, and in such cases, aggressive biopsy should be considered.
Source: Respirology Case Reports - Category: Respiratory Medicine Authors: Osamu Kanai, Koichi Nakatani, Kohei Fujita, Misato Okamura, Tadashi Mio Tags: Case Report Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | CT Scan | Interstitial Lung Disease | Lung Cancer | Non-Small Cell Lung Cancer | Pneumonia | Respiratory Medicine | Toxicology